Drug Trial Radar · NCT00850746
A Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Mar 24, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Feb 2009
Primary completion
Apr 2009
Study completion Apr 2009
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Feb 25, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study evaluates whether YM443 causes any changes in the electrocardiogram of healthy adults.
Conditions
- Functional Dyspepsia
Interventions
YM443Drug
Oral
PlaceboDrug
Oral
MoxifloxacinDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change in the QTcF (Fridericia's correction) between each active treatment and placeboTime frame: Following four days of dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Tacoma, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.